Literature DB >> 17525226

Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials.

Benjamin C M Chang1, Giuseppe Mirabella, Ronit Yagev, Michael Banh, Eedy Mezer, Patricia C Parkin, Carol A Westall, J Raymond Buncic.   

Abstract

PURPOSE: Neurofibromatosis type 1 (NF-1) is an autosomal dominant phakomatosis with a prevalence of 1 in 2000 to 1 in 5000. Up to 24% of these patients have optic pathway gliomas (OPGs). In the present study, the use of sweep visual evoked potentials (SVEPs) was investigated as a screening tool for identifying patients with NF-1 who had OPGs by comparing them to those patients with no OPGs and to normally developing children.
METHODS: Contrast sensitivity and grating acuity were measured with the SVEP. Sixteen children with OPGs (OPG group), 14 children with NF-1 without OPGs (nOPG), and 16 aged-matched control subjects were recruited. All participants had best-corrected visual acuity of 6/9 or better. All were tested monocularly.
RESULTS: Comparisons between groups by using the Tukey B test showed a significant reduction of mean log contrast sensitivity in the OPG group (1.55) compared with the nOPG (1.9, P = 0.006) and control (2.10, P < 0.001) group. There was no significant difference between the nOPG and control groups (P = 0.195). Grating acuity was comparable between groups, and no statistically significant differences were found. Log contrast sensitivity was moderately sensitive in identifying patients with OPG and was highly specific in screening out patients with no OPG.
CONCLUSIONS: Children with OPGs have reduced contrast sensitivity when assessed using the SVEP. Children with no OPGs display no differences in visual functioning compared with control subjects. The findings suggest that the SVEP can be a useful and noninvasive screening tool for early detection of visual pathway gliomas in children with NF-1 and normal visual acuity.

Entities:  

Mesh:

Year:  2007        PMID: 17525226     DOI: 10.1167/iovs.06-0429

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Retinal nerve fiber layer thickness in children with optic pathway gliomas.

Authors:  Robert A Avery; Grant T Liu; Michael J Fisher; Graham E Quinn; Jean B Belasco; Peter C Phillips; Maureen G Maguire; Laura J Balcer
Journal:  Am J Ophthalmol       Date:  2011-01-12       Impact factor: 5.258

Review 2.  Role of visual evoked potentials in the assessment and management of optic pathway gliomas in children.

Authors:  C Van Mierlo; W Spileers; E Legius; I Casteels; C Cassiman
Journal:  Doc Ophthalmol       Date:  2013-07-25       Impact factor: 2.379

3.  Handheld optical coherence tomography during sedation in young children with optic pathway gliomas.

Authors:  Robert A Avery; Eugene I Hwang; Hiroshi Ishikawa; Maria T Acosta; Kelly A Hutcheson; Domiciano Santos; Dina J Zand; Lindsay B Kilburn; Kenneth N Rosenbaum; Brian R Rood; Joel S Schuman; Roger J Packer
Journal:  JAMA Ophthalmol       Date:  2014-03       Impact factor: 7.389

Review 4.  Visual function tests including the role of optical coherence tomography in neurofibromatosis 1.

Authors:  Daphna Mezad-Koursh; Anat Bachar Zipori; Dinah Zur; Lior Degabli; Meital Ben-Dov; Ainat Klein
Journal:  Childs Nerv Syst       Date:  2020-08-04       Impact factor: 1.475

Review 5.  Optic pathway gliomas: a review.

Authors:  Iris Fried; Uri Tabori; Tarik Tihan; Arun Reginald; Eric Bouffet
Journal:  CNS Oncol       Date:  2013-03

6.  Paradoxical robust visual evoked potentials in young patients with cortical blindness.

Authors:  Tamara Wygnanski-Jaffe; Carole M Panton; J Raymond Buncic; Carol A Westall
Journal:  Doc Ophthalmol       Date:  2009-06-23       Impact factor: 2.379

7.  Functional outcome measures for NF1-associated optic pathway glioma clinical trials.

Authors:  Michael J Fisher; Robert A Avery; Jeffrey C Allen; Simone L Ardern-Holmes; Larissa T Bilaniuk; Rosalie E Ferner; David H Gutmann; Robert Listernick; Staci Martin; Nicole J Ullrich; Grant T Liu
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.